Related Experiment Video
Updated: Jul 27, 2025
13:13
High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry
Published on: September 23, 2014
30.4K
Growth Differentiation Factor 15 (GDF-15), a New Biomarker in Heart Failure Management.
Khalid Sawalha1,2, Nicholas B Norgard3, Betty M Drees4
1Cardiometabolic Medicine Fellowship, University of Missouri-Kansas City, Kansas City, MO, USA. Ksawalha@aol.com.
Current Heart Failure Reports
|June 8, 2023
Summary
Biomarkers aid medical diagnosis and prognosis. Growth Differentiation Factor (GDF)-15 shows promise as a novel biomarker for predicting heart failure (HF) morbidity and mortality.
Area of Science:
- Biomedical science
- Cardiovascular medicine
- Biomarker research
Background:
- Biomarkers are crucial for disease screening, diagnosis, characterization, monitoring, and prognosis.
- Natriuretic peptides are current gold standards for heart failure (HF) diagnosis and prognostication.
- The clinical utility of natriuretic peptides for HF treatment monitoring remains under investigation.
Purpose of the Study:
- To review the evolving role of biomarkers in medicine, particularly in heart failure (HF).
- To highlight emerging biomarkers for HF diagnosis and prognosis.
- To emphasize the potential of Growth Differentiation Factor (GDF)-15 as a prognostic biomarker for HF.
Main Methods:
- Literature review of current biomarker applications in medicine and cardiology.
- Analysis of existing and emerging biomarkers for heart failure (HF).
- Focus on the prognostic potential of Growth Differentiation Factor (GDF)-15 in HF.
Main Results:
- Biomarkers offer advantages over traditional clinical endpoints in terms of ease, cost, and speed of measurement.
- While natriuretic peptides are widely used, other biomarkers are under investigation for HF.
- No current novel biomarkers are HF-specific or recommended for routine clinical use.
- Growth Differentiation Factor (GDF)-15 demonstrates potential for providing prognostic information in HF.
Conclusions:
- Biomarkers are integral to modern medicine, offering versatile applications.
- Growth Differentiation Factor (GDF)-15 is a promising emerging biomarker for predicting heart failure (HF) outcomes.
- Further research is needed to validate GDF-15 and other novel biomarkers for routine clinical practice in HF.
More Related Videos
Related Concept Videos
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:30Heart Failure IV: Classification and Diagnostic Evaluation
21
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
21
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
12
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
12
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
127
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
127